Pfizer (PFE) Stock Analysis & Winston Score
Pfizer is one of the largest pharmaceutical companies in the world. It discovers, manufactures, and sells prescription medicines and vaccines to hospitals, pharmacies, doctors, and governments. Its well-known products include the Prevnar vaccine, the blood thinner Eliquis, and the COVID-19 vaccine it developed with BioNTech. Pfizer makes most of its money by selling patented drugs at premium prices, then earning royalties and licensing fees on some products. It operates in over 125 countries and generates roughly half its revenue outside the United States. Its main competitive advantage is its large portfolio of patented medicines, which block competitors for years, along with its massive research and manufacturing infrastructure. The biggest risk Pfizer faces is patent expiration — several of its top-selling drugs will lose patent protection by the late 2020s, which could sharply reduce revenue unless new drugs from its pipeline successfully replace those sales.
Winston Score: 47/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Good (17/30)
- Growth: Weak (3/20)
- Cash Flow: Exceptional (9/10)
- Stability: Good (6/10)
- Valuation: Strong (8/10)
- Ownership: Weak (1/15)
Key Facts
Price: $25.05
Market Cap: $142.8B
Sector: Healthcare
Industry: Drug Manufacturers - General


